The nation of Zimbabwe has rejected a major American health deal valued at $367m (272 million pounds) spanning five years over the United States' request for confidential data.
This rejection became public after a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson has since explained that the United States was demanding access to genetic material for scientific study and commercial gain while was unwilling to share the benefits from future medical innovations.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more dialogue to find a deal acceptable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Background
Zimbabwe's decision follows a similar situation in Kenya, where a high court suspended a related deal with the US after legal challenges were raised about the security of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral agreements to boost transparency and accountability.
Based on reports, 16 African countries have to date agreed to similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving HIV treatment through US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be available to our citizens should a future pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of bilateral deals were undermining systems already set up via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This system is designed to ensure that when a country contributes its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We encourage further dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that honours the independence and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but urged that talks must proceed since a large portion of the nation's Aids initiatives relied on foreign aid.
"If technical issues arise, such as those relating to data governance or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," the group added.
The situation highlights the ongoing debate between receiving crucial foreign assistance and protecting local interests in an ever more data-driven world.